Best Rheumatology Journals (2026): Ranked by Impact and Accessibility

This journal publishes only review articles, commentaries, and perspectives, and almost all content is commissioned. You won't send original data here. But if you're recognized as an expert in your area, an editorial team invitation to write a review for Nature Reviews Rheumatology is one of the highest honors in the specialty. The reach extends well beyond rheumatology into immunology and internal medicine.

ARD is the flagship of EULAR and arguably the most influential rheumatology journal for original research. It has an unusually high impact factor for a specialty journal, driven partly by its role in publishing EULAR recommendations and major clinical trial results. The review process is fast and rigorous. ARD favors papers that will change clinical practice or fundamentally shift understanding of rheumatic diseases. If you have a multicenter RCT or a large epidemiological study with clear clinical implications, ARD is the target.

This is the ACR's flagship journal and the top US-based rheumatology title. It publishes strong original research across clinical, translational, and basic science domains. The journal has a slight preference for mechanistic work compared to ARD's clinical emphasis, which makes it a better fit for studies that bridge bench and bedside. Review quality is generally high, and the editorial team provides constructive feedback even on rejected manuscripts.

Launched relatively recently as part of the Lancet family, this journal has quickly established itself as an elite venue for clinical rheumatology. It's fully open access with a corresponding APC, and it focuses on clinical trials, large cohort studies, and health policy research. The Lancet brand gives papers enormous visibility outside the specialty.

The BSR's official journal is a consistent, well-edited publication that sits comfortably in the strong tier. It accepts a broader range of study designs than the elite journals and is particularly receptive to epidemiological work, systematic reviews, and clinical outcome studies. If your paper is solid but doesn't quite reach ARD's novelty threshold, Rheumatology is an excellent step down that won't feel like a compromise.

Despite its name suggesting review content, this journal also publishes original research. It's a good fit for thorough systematic reviews, meta-analyses, and large observational studies. The review process can be slow, but the journal carries genuine respect in the field, especially for review articles.

JRheum is a Canadian journal with a long history and loyal readership. It publishes across all of clinical rheumatology and is particularly strong in outcomes research, disease registries, and validated measurement tools. The review process tends to be thorough but can be slow. A solid choice for well-designed clinical studies.

This BioMed Central journal is fully open access and has built a strong reputation for translational rheumatology research. It's a good home for well-designed studies that connect basic science findings to clinical outcomes. The acceptance rate around 30% is realistic for many research groups, and the OA model ensures broad readership.

EULAR's open access journal was created as a companion to ARD, and it's established itself as more than a spillover venue. It publishes original research, systematic reviews, and recommendations with a European focus. The connection to EULAR gives it visibility at conferences, and the APC is reasonable by current standards.

The French Society of Rheumatology's journal publishes solid clinical research with a European perspective. It's a reasonable target for single-center studies, cohort analyses, and observational research. The journal is indexed in all major databases and has a stable readership.

If you need a home for well-written case reports, small cohort studies, or regional epidemiological work, Clinical Rheumatology is a pragmatic choice. The acceptance rate is higher than most, and the turnaround is predictable. It's not glamorous, but it's indexed, read, and cited.

This disease-focused journal is the natural home for lupus research that doesn't reach the generalist rheumatology journals. It covers clinical, translational, and epidemiological aspects of SLE and related conditions. If your study population is specifically lupus patients, consider Lupus before a generalist title where your work might get lost.

If your paper is a large multicenter RCT, ARD or Lancet Rheumatology should be your first targets. Both prioritize practice-changing clinical evidence.

If your paper connects basic science to clinical outcomes, Arthritis & Rheumatology is ideal. It values mechanistic work more than other top journals in the field.

If your paper is a well-designed observational study, Rheumatology (Oxford) or Journal of Rheumatology offer good fits. Both welcome epidemiological and outcomes research.

If your paper is a systematic review or meta-analysis, Seminars in Arthritis and Rheumatism has long been the preferred venue. RMD Open is also increasingly receptive.

If your paper needs open access and you have limited funding, RMD Open and Arthritis Research & Therapy both offer reasonable APCs with strong visibility.

If your paper is disease-specific (lupus, vasculitis, scleroderma), consider specialty journals like Lupus before generalist titles. Your audience is already reading there.